The review found no eligible studies for this question.
The review found no eligible studies for this question.
S‐adenosyl methionine as monotherapy may leads to lower acceptability. Participants experiencing troublesome adverse effects… compared with tricyclic antidepressant agent (low certainty).
S‐adenosyl methionine as monotherapy showed no clear difference in acceptability Participants dropping out of treatment during the… compared with SSRI antidepressant agent (low certainty).
S‐adenosyl methionine as monotherapy showed no clear difference in proportions of participants responding to treatment ≥ 50% reduction… compared with SSRI antidepressant agent (low certainty).
S‐adenosyl methionine as monotherapy showed no clear difference in proportions of participants achieving remission depression rating… compared with SSRI antidepressant agent (low certainty).
The review found no eligible studies for this question.
S‐adenosyl methionine as monotherapy showed no clear difference in acceptability Participants dropping out of treatment during the… compared with placebo (low certainty).
S‐adenosyl methionine as monotherapy showed no clear difference in proportions of participants responding to treatment ≥ 50% reduction… compared with placebo (low certainty).
S‐adenosyl methionine as monotherapy showed no clear difference in proportions of participants achieving remission Depression rating… compared with placebo (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether S‐adenosyl methionine as monotherapy changes acceptability Participants dropping out of treatment during the… compared with tricyclic antidepressant agent (very low certainty).
It is very uncertain whether S‐adenosyl methionine as monotherapy changes proportions of participants responding to treatment ≥ 50% reduction… compared with tricyclic antidepressant agent (very low certainty).
The review found no eligible studies for this question.